title: IFN-beta decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome.
abstract: The adhesion capacities, transmigration capacities, and integrin expression of lymphocytes from patients with Guillain-Barré syndrome incubated with interferon-beta were studied. Interferon-beta induced a dose-dependent inhibition of lymphocyte adhesion to recombinant vascular adhesion molecule-1 (p < 0.0001) and recombinant intercellular adhesion molecule-1 (rICAM-1) (p < 0.01) without modulation of very late activation molecule-4 and lymphocyte function-associated antigen-1 expressions and a dose-dependent decrease of lymphocyte transmigration across fibronectin (p < 0.0001). Inhibition of adhesion to rICAM-1 was similar after long (18 hours) or short (5 minutes) incubation time. These results support the potential therapeutic benefit of interferon-beta in Guillain-Barré syndrome.
authors.affiliation: Réseau de Neuroimmunologie du Nerf Périphérique (AP/HP), Service de Neurologie, Hôpital Henri Mondor, Creteil Cedex, France. creange@univ-paris12.fr
authors.forename: A
authors.initials: A
authors.lastname: Créange
authors.forename: B
authors.initials: B
authors.lastname: Chazaud
authors.forename: A
authors.initials: A
authors.lastname: Plonquet
authors.forename: T
authors.initials: T
authors.lastname: Sharshar
authors.forename: F
authors.initials: F
authors.lastname: Poron
authors.forename: C
authors.initials: C
authors.lastname: Sonnet
authors.forename: J C
authors.initials: JC
authors.lastname: Raphaël
authors.forename: R K
authors.initials: RK
authors.lastname: Gherardi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D020275:Guillain-Barre Syndrome / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D039041:Integrin alpha4beta1; D016023:Integrins / Q000032:analysis; D016899:Interferon-beta / Q000008:administration & dosage*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000032:analysis; D008214:Lymphocytes / Q000737:chemistry / Q000166:cytology*; D016201:Receptors, Lymphocyte Homing / Q000032:analysis; D019010:Vascular Cell Adhesion Molecule-1 / Q000494:pharmacology
chemical_list: D000276:Adjuvants, Immunologic; D039041:Integrin alpha4beta1; D016023:Integrins; D016169:Lymphocyte Function-Associated Antigen-1; D016201:Receptors, Lymphocyte Homing; D019010:Vascular Cell Adhesion Molecule-1; D016899:Interferon-beta